$MNPR

Monopar Therapeutics Inc

  • NASDAQ
  • Health Technology
  • Biotechnology

PRICE

$4.78 ▲4.367%

Extented Hours

VOLUME

8,600

DAY RANGE

4.57 - 4.9399

52 WEEK

4.28 - 17.01

Join Discuss about MNPR with like-minded investors

PR
@proj8 #StockTraders.NET
recently

$MNPR low float p&d

56 Replies 12 👍 9 🔥

JR
@jrutkows645 #StockTraders.NET
recently

$PSTV on 8/7 and $MNPR on 8/12 are both examples of ITM dilutoin plays with no volume

140 Replies 6 👍 14 🔥

JR
@jrutkows645 #StockTraders.NET
recently

$MNPR really tapping into that ATM

67 Replies 14 👍 15 🔥

Key Metrics

Market Cap

57.63 M

Beta

0.53

Avg. Volume

18.15 K

Shares Outstanding

12.58 M

Yield

0%

Public Float

0

Next Earnings Date

2021-11-11

Next Dividend Date

Company Information

Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stagepreclinical antibody, MNPR-101, for advanced cancers and severe COVID-19.

Website:

HQ: 1000 Skokie Blvd Ste 350 Wilmette, 60091-1146 Illinois

Related News